Buscar

Mostrando ítems 1-4 de 4

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis

2020- Gladman, D. D.; Orbai, A. M.; Gómez-Reino Carnota, Juan Jesús; Chang-Douglass, S.; Leoncini, E.; [et al.]

Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies

2020- Ritchlin, C. T.; Giles, J. T.; Ogdie, A.; Gómez-Reino Carnota, Juan Jesús; Helliwell, P.; [et al.]

Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register

2020- Vela, Paloma; Sanchez-Piedra, Carlos; Perez-Garcia, Carolina; Castro-Villegas, María C; Freire Gonzalez, Mercedes; [et al.]

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies

2020- Sanchez-Piedra, C.; Diaz-Torne, C.; Manero, J.; Pego Reigosa, José María; Rua-Figueroa, I.; [et al.]